Tag Archives: pharma

New PhRMA Report: Nearly 300 Vaccines Currently in Development

flu-syringe

Today, the Pharmaceutical Research and Manufacturers of America released a report, Medicines in Development: Vaccines – A Report on the Prevention and Treatment of Disease Through Vaccines. The report shows that U.S. biopharma companies are currently developing 271 vaccines to prevent and treat numerous conditions, including infectious diseases and various forms of cancer and neurological disorders. Vaccines have successfully prevented devastating infectious diseases such as smallpox, measles and polio. According to data from the Centers Read More >

Health  |  1 Comment  |  Email This Post
Tags: , , , ,

Patients are the Missing Link in R&D

Elias Zerhouni

An architect does not wait until construction begins to show clients a blueprint. Neither does a caterer prepare a banquet meal without consulting first with the host. In biopharmaceutical science, however, for too long we have developed medicines without engaging patients early on and throughout the process. If scientific innovation is to truly be innovative, we need to be more interested in the people our products will help. We need to rethink innovation. The model we’ve used in healthcare Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

BIO-Europe Spring Opening Remarks

Chart

BIO’s own David Thomas, Director of Industry Research, delivered opening remarks at the BIO-Europe Spring conference in Barcelona yesterday. His slides provide a snapshot of the biotech industry’s performance and highlight emerging trends in venture exits: IPOs and M&A. Takeaways from his talk include breakouts on multiple fronts for the industry: FDA approvals at highs not seen since the 1990s Orphan designation approvals at all-time highs IPOs starting to show signs of life in 2012 Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

Putting a Ring on It: Advice on Successful Drug Development Collaborations

Ring

Drug development partnerships can look lucrative to small biotechs eager to monetize their discoveries, but, like any relationship, these tie-ups take work and both parties run the risk of ending up in tears. At BIO’s recent CEO & Investor Conference, a panel of industry veterans gathered to discuss best practices in drug development partnering. Moderated by Jeff Stewart, Senior Engagement Manager with Campbell Alliance, the panel “Putting a Ring on it: When Drug Development Partnerships Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

Biobuck M&A in Full Gear

Graph

The 2012 M&A results are in and trends are mixed. Last year was a down year in terms of total acquisitions and total dollar value amounts vs 2011.  What was not down however was the earnout structures embedded in these deals. More and more M&A transactions are looking like partnering deals structured with CVRs accounting for the bolus of the reported purchase price. Here is a look at therapeutic-focused acquisitions (valued at >$10M) over the Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , ,